Pharsight

Melinta patents expiration

1. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 3 months from now)

US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(2 years from now)

US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(5 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

US8497378 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 3 months from now)

US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(1 year, 3 months from now)

US8252813 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2026

(2 years from now)

US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027
New Indication(I-815) Oct 24, 2022

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: POWDER;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

BAXDELA family patents

Family Patents